Traditional treatment

PreclinicalSmall molecule

UUniversity of Alabama at Birmingham

Traditional treatment is one of 87 small molecule programs targeting Dysmenorrhea. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DysmenorrheaActive, not recruiting

InsomniaRecruiting

Status EpilepticusActive, not recruiting

DysmenorrheaPreclinical

Active, not recruiting

InsomniaPreclinical

Recruiting

Status EpilepticusPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

153 competitors in Insomnia

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

1 2

Hetlioz

VVanda Pharmaceuticals

Phase 3

2 3

Eplivanserin

Sanofi

Phase 3

6 4

Volinanserin

Sanofi

Phase 3

2 5

Prosom

AAbbott

Phase 3

4 6

Org 50081

Merck & Co.

Phase 3

1 7

Nitrazepam

Astellas

Phase 3

1 8

MK0928, Gaboxadol

Lundbeck

Phase 3

5 9

Zolpidem MR

Astellas

Phase 3

4 10

TS-142

TTaisho Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Insomnia

NCT07357779

Clinical

Trials by Indication[1]

Dysmenorrhea1 trial

Transcutaneous Tibial Nerve Stimulation on Women With Primary Dysmenorrhea

Recruiting·KKafrelsheikh University·N/A·NCT07352982·32 enrolled

Status Epilepticus1 trial

Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus

Withdrawn·UUniversity of Alabama at Birmingham·Phase 2/3·NCT03115489

Insomnia1 trial

Clinical Efficacy and Health Economic Evaluation of an Intelligent Diagnostic and Treatment Model Based on Digital Cognitive Behavioral Therapy for Insomnia Disorder

Recruiting·ZZan Wang·Preclinical·NCT07357779·404 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Traditional treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Traditional treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Traditional treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Alabama at Birmingham

Traditional treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Dysmenorrhea1 trial

Status Epilepticus1 trial

Insomnia1 trial

References

Drug Info

Quick Facts

Related News